Tapering GLP-1 Doses: What the Research Says

Tapering isn't just a cautious-sounding idea — there's now a detailed body of research behind it, including one study that followed hundreds of people through a structured dose reduction and tracked exactly what happened to their weight afterward.

The core study: what actually happened to 353 people

A study presented at the 2024 European Congress on Obesity offers the most detailed tapering data currently available. Researchers gradually reduced the dose of semaglutide to zero over nine weeks for 353 individuals who wished to discontinue after reaching their target weight, while coaching them on exercise and diet throughout the process (MedCentral, 2025).

Of those 353 people, 240 successfully tapered all the way to zero (MedCentral, 2025). Among a subgroup of 85 individuals followed for 26 weeks after completing the taper, weight remained stable — with an average weight loss (not gain) of 1.5% after complete withdrawal (MedCentral, 2025). This is a genuinely striking finding: not just weight maintenance, but a small continued loss, months after the medication had been fully withdrawn.

The same study also found something clinically useful for treatment overall: lower doses of semaglutide were as effective as higher doses in this cohort, and slowly reducing the dosage while focusing on lifestyle changes specifically helped prevent the weight regain typically associated with stopping (MedCentral, 2025).

What happened to the people who restarted

The study also tracked what happened to people who went back on the medication. Of the 240 who completed the taper, 46 people reinitiated semaglutide, with an average weight gain of 1.3% occurring between stopping and restarting (MedCentral, 2025). This is a useful, honest data point: even among people who did eventually need to restart, the amount of regain in that window was modest — nothing close to the dramatic rebound seen in abrupt-discontinuation data.

How this compares to abrupt discontinuation in trial data

The contrast with stopping without any taper is stark. In the STEP 1 trial extension, by week 120 the group that had been switched to placebo regained a mean of 11.6 percentage points of previously lost weight, compared with 1.9 percentage points in a group that had never been on the active medication at all — translating to net losses of just 5.6% versus a starting position, compared with 0.1% for the reference group (MedCentral, 2025). A similar pattern was seen in the SURMOUNT-4 trial for tirzepatide, where people who discontinued and switched to placebo regained an average of 14% of the weight they had lost (MedCentral, 2025).

Set against the tapered cohort's 1.5% average loss at 26 weeks, the difference between an abrupt stop and a structured nine-week taper is substantial.

What a typical tapering schedule actually looks like

There's no single universal tapering protocol currently established (Diabetes in Control, 2026), but a common clinical approach is worth understanding. Many clinicians step the dose down using the same intervals that were used during the original dose escalation — meaning if your dose was increased every four weeks on the way up, a similar four-week interval is often used stepping back down (Diabetes in Control, 2026). This approach allows appetite regulation and glycaemic control to adjust gradually, rather than dropping suddenly (Diabetes in Control, 2026).

An alternative approach studied more recently involves spacing doses out rather than reducing the amount per dose — for example, moving from a weekly injection to an every-other-week schedule. This method has shown promise for helping people maintain a substantial portion of their weight loss during the transition (referenced in our companion piece on coming off a GLP-1 without regaining weight).

Why framing the decision matters, not just the mechanics

According to the American Diabetes Association's Standards of Care, obesity and type 2 diabetes are chronic conditions requiring individualised, ongoing management — which is exactly why the decision to taper should be collaborative and structured with your prescriber, rather than abrupt (Diabetes in Control, 2026). There's a genuinely interesting behavioural point buried in this clinical guidance: when treatment is framed from the start as part of long-term disease management, tapering feels like a planned transition rather than a sudden withdrawal — and that shift in perspective alone appears to improve outcomes (Diabetes in Control, 2026).

Why coaching was built into the research itself, not added afterward

It's worth noting explicitly that the 353-person taper study didn't test dose reduction in isolation — participants were coached on exercise and diet throughout the entire nine-week process (MedCentral, 2025). The tapering schedule and the behavioural coaching were part of the same intervention, not two separate things layered together after the fact. This matters for how you think about your own transition: the research behind tapering's success isn't really "reduce the dose slowly" on its own — it's "reduce the dose slowly while actively working on the habits that will sustain you afterward."

Building your own tapering plan around this evidence

Given what the research shows, a few principles are worth taking into any conversation with your prescriber about tapering:

• A roughly nine-week timeframe, reducing dose at intervals, has real study data behind it — worth asking your prescriber whether a similar schedule makes sense for your situation.

• Coaching on diet and exercise throughout the taper, not just before or after it, appears to be part of what made the studied approach work.

• Even a modest restart is a data point, not a failure — the study's own restart cohort saw only modest regain before going back on treatment, suggesting the process itself doesn't need to be treated as all-or-nothing.

This is precisely the model our Coming Off It programme is built around — a structured tapering timeline paired with active nutrition and training coaching throughout, mirroring the approach the actual research studied rather than dose reduction alone.

If you're building toward that transition and want to strengthen your habits while still on treatment, our While You're On It programme lays that groundwork in advance.

Protein intake remains just as important throughout a taper as during active treatment — our Alongside Daily Support powder can help you stay consistent through the transition.

And if you want a tapering and coaching plan built specifically around your own schedule and prescriber's guidance, our 1:1 coaching can help you put that together.

The bottom line

The research on tapering GLP-1 doses now includes real, detailed data: a structured nine-week reduction combined with lifestyle coaching helped a cohort of 353 people maintain, and in many cases continue improving, their weight for at least 26 weeks afterward — a dramatically different outcome from the substantial regain seen with abrupt discontinuation in major trials. There's no single universal protocol yet, but the direction of the evidence is consistent: gradual reduction, paired with active coaching throughout, is where the strongest results currently sit.

This article is for general information and isn't a substitute for medical advice. Any tapering schedule should be planned and supervised by your prescriber.

References

Diabetes in Control. (2026, February 15). GLP-1 tapering: When and how to stop safely. https://www.diabetesincontrol.com/glp-1-tapering-strategies/

MedCentral. (2025, December 31). Weight maintenance after GLP-1 RA withdrawal exposes critical research gaps. https://www.medcentral.com/endocrinology/obesity/weight-maintenance-after-glp-1-ra-withdrawal-exposes-critical-research-gaps

WeightWatchers. (2026, March 23). Weaning off GLP-1s: How to taper off your GLP-1. https://www.weightwatchers.com/us/blog/weight-loss/tapering-off-glp-1